
Annual births fall to another record low in Japan as its population emergency deepens
TOKYO — The number of newborns in Japan is decreasing faster than projected, with the number of annual births falling to another record low last year, according to government data released Wednesday.
The Health Ministry said 686,061 babies were born in Japan in 2024, a drop of 5.7% on the previous year and the first time the number of newborns fell below 700,000 since records began in 1899. It's the 16th straight year of decline.
It's about one-quarter of the peak of 2.7 million births in 1949 during the postwar baby boom.
The data in a country of rapidly aging and shrinking population adds to concern about the sustainability of the economy and national security at a time it seeks to increase defense spending.
Prime Minister Shigeru Ishiba has described the situation as 'a silent emergency' and has promised to promote more flexible working environment and other measures that would help married couples to balance work and parenting, especially in rural areas where family values tend to be more conservative and harder on women.
Japan is one of a number of east Asian countries grappling with falling birth rates and an aging population. South Korea and China have fought for years to encourage families to have more children. Also on Wednesday, Vietnam scrapped decades-old laws limiting families to two children in an effort to stem falling birth rates.
The Health Ministry's latest data showed that Japan's fertility rate — the average number of babies a woman is expected to have in her lifetime — also fell to a new low of 1.15 in 2024, from 1.2 a year earlier. The number of marriage was slightly up, to 485,063 couples, but the downtrend since the 1970s remains unchanged.
Experts say the government's measures have not addressed a growing number of young people reluctant to marry, largely focusing on already married couples.
The younger generation are increasingly reluctant to marry or have children due to bleak job prospects, a high cost of living and a gender-biased corporate culture that adds extra burdens for women and working mothers, experts say.
A growing number of women also cite pressure to take their husband's surname as a reason for their reluctance to marry. Under Japanese law, couples must choose a single surname to marry.
Japan's population of about 124 million people is projected to fall to 87 million by 2070, with 40% of the population over 65.
Mari Yamaguchi, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
a day ago
- Globe and Mail
Wet Age-Related Macular Degeneration (Wet-AMD) Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Wet Age-Related Macular Degeneration Companies are Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. (Albany, USA) DelveInsight's ' Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market. Key Takeaways from the Wet Age-Related Macular Degeneration Market Report In May 2025, Kodiak Sciences Inc announced results of a Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In May 2025, NexThera Co., Ltd announced results of a Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD) In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023. The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future. Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases). Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM. Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023. The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023. Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases). Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM. In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand). The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR. The leading Wet Age-Related Macular Degeneration Companies such as Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Marketed Drugs • BEOVU (Brolucizumab): Novartis BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules. • EYLEA (aflibercept): Regeneron Pharmaceuticals EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials. • VABYSMO (faricimab): Roche/ Genentech, Inc. VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels. Wet Age-Related Macular Degeneration Emerging Drugs • OPT-302: Opthea Limited OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. • KSI-501: Kodiak Sciences Inc. KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. Wet Age-Related Macular Degeneration Market Outlook Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients. The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion. Wet Age-Related Macular Degeneration Drugs Uptake The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration. Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others Scope of the Wet Age-Related Macular Degeneration Market Report Coverage- 7MM Study Period- 2020-2034 Wet Age-Related Macular Degeneration Companies- Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals Table of Content 1 Key Insights 2 Report Introduction 3 Wet AMD Market Overview at a Glance 4 Wet AMD Market: Future Perspective 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 Marketed Drugs 11 Emerging Drugs of Wet AMD 12 Wet AMD: Market Analysis 13 Key Opinion Leaders' Views 14 SWOT Analysis 15 Unmet Needs 16 Market Access and Reimbursement 17 Appendix 18 DelveInsight Capabilities 19 Disclaimer About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:


Globe and Mail
a day ago
- Globe and Mail
Collagen & Gelatin Market worth US$1,671.3 million in 2030 5.8% CAGR
"The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel)" Browse 280 market data Tables and 53 Figures spread through 252 Pages and in-depth TOC on "Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Orthopedic, Cardiovascular, Dental, Surgical), Competitive Landscape (Company Profile, Market share, Company Evaluation Matrix), End User, and Region - Global Forecast to 2030 The global Collagen & Gelatin Market, valued at US$1,203.9 million in 2024, is forecasted to grow at a robust CAGR of 5.8%, reaching US$1,295.5 million in 2025 and an impressive US$1,671.3 million by 2030. Growing incidence of diabetes, cancer, and chronic diseases; rising demand for advanced wound care products; surge in surgical procedures; increasing use in tissue engineering and regenerative medicine; extensive application of collagen as a drug delivery system are driving the market. Browse in-depth TOC on " Collagen & Gelatin Market" 228 - Tables 44 - Figures 240 - Pages By Based on segment, the collagen & gelatin market is divided into bovine, porcine, and others. The large share of the bovine segment can be attributed to the growing adoption of bovine-derived collagen and gelatin in regenerative medicine. Additionally, the increased usage of biomaterials is primarily due to the biocompatibility and biodegradability properties exhibited by these materials. By Based on application, The collagen market is segmented into orthopaedic, wound care, dental, surgical, cardiovascular, and other applications. In 2024, the orthopaedic application segment accounted for the largest share of the collagen market by applications due to the rising demand for scaffolds and substitutes due to their extensive use in orthopaedic surgeries. This dominance is expected to continue throughout the forecast period due to the rising number of road trauma cases. By geography, the collagen & gelatin market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America held the largest share of the collagen & gelatin market, followed by Europe. Asia Pacific registered the highest CAGR growth within the collagen & gelatin market during the forecast period due to its increasing application for research and clinical diagnostics, adoption of collagen & gelatin for transplantation-associated research, and government initiatives and industrial collaboration. The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel), Collagen Solutions plc (UK), Regenity (US), Medtronic plc (Ireland), and Solventum (US). INTEGRA LIFESCIENCES (US): Integra LifeSciences leads in the collagen & gelatin market. It operates through two business segments, namely Codman Specialty Surgical and Tissue Technologies. The company offers engineered bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh products through its Tissue Technologies Segment. This segment recorded a decline of 3.3% in 2024 over 2023 due to the impact of the lost revenue related to the Boston product recall, which was partially offset by double-digit growth from BioD and Gentrix and mid-single-digit growth in Integra skin and MediHoney. The company's leading position is attributable to its diversified product portfolio, geographical expansion, and adoption of organic and inorganic growth strategies. For instance, in March 2024, Integra Life Sciences received an US FDA approval to commercialize a dermal regeneration template for repairing scar contractures. SMITH+NEPHEW PLC (UK): Smith+Nephew is one of the leading players in the collagen & gelatin market due to its robust portfolio, including innovative collagen-based scaffolds and collagenase-based enzymatic debridement agents. The company operates through three business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers collagen and gelatin products through its advanced wound management business segment. Additionally, the company's strong global presence, strategic partnerships, and commitment to customer-centric solutions position it as a key player in the competitive collagen and gelatin space. The company possesses a strong geographical presence with a broad range of distribution networks to solidify its leadership in the collagen and gelatin market. The advanced wound management business segment of Smith+Nephew has experienced a positive growth rate of 4.7% in the year 2024 and maintained positive momentum in 2024, with growth accelerating toward the end of the year. For more information, Inquire Now!

National Post
a day ago
- National Post
BGO Announces US$5.1 Billion Capital Raise for Its Asia Value-Add Real Estate Strategy, Marking Largest Closed-End Fundraise in Firm's History
Article content TOKYO — BGO today announced the final close of BentallGreenOak Asia IV ('BGO Asia Fund IV' or the 'Fund'), its flagship Asia-focused value-add real estate strategy, raising over US$5.1 billion in total capital commitments for the Fund and co-investment sidecars. The Fund represents the largest closed-end capital raise in BGO's history, underscoring the firm's history and reputation as a premier global real estate investment manager in Asian markets. Article content BGO Asia Fund IV targets value-add opportunities in office, hospitality, and logistics assets across Japan, South Korea, Australia, and Singapore. Japan represents a central pillar of our investment strategy, driven by regulatory reforms and corporate governance shifts that are catalyzing an estimated US$3 trillion in non-core asset divestitures. Article content 'Japan is undergoing a profound transformation, and we see strong, sustained tailwinds across the region,' said Fred Schmidt, Managing Partner and Chairman of Asia, BGO. 'Tokyo is one of the world's largest and most dynamic commercial real estate markets, and with growing pressure on Japanese corporations to optimize their corporate value, our deep roots and integrated presence positions us well to access opportunities others might miss. This Fund has over 3 trillion JPY investing power.' Article content Backed by 45 institutional limited partners, the Fund received support from a highly diversified global investor base. Notably, 44% of the capital was sourced from the United States, 24% from Asia, and 23% from the Middle East, with the remainder coming from Canada and Europe. Article content The Fund's investor participation reflects sustained confidence in BGO's Asia platform and increased interest in the region: Article content One-third of commitments came from existing Asia fund investors who have previously invested in this strategy; One-third from longstanding BGO clients expanding into the Asia value-add strategy; and One-third from new investors entering a BGO vehicle for the first time. Article content 'We are honored by the trust of our long-standing partners and pleased to welcome new investors who share our vision for capturing value across Asia's most compelling urban markets,' said Marcus Merner, Managing Partner and Head of Asia, BGO. 'Our team, our consistent track record in Asia, our local expertise are important differentiators.' Article content BGO's Asia team brings decades of continuity and cycle-tested experience. The leadership team—including Sonny Kalsi (co-CEO), Fred Schmidt (Chairman of Asia), Marcus Merner (Head of Asia), Dan Klebes (Head of Japan) and Jeannie Kim (Head of Korea) — brings an average of almost 30 years of investing experience in Asia. Article content Importantly, BGO operates a fully vertically integrated platform in Japan, executing 100% of its investments in-house. The firm's regional team now includes more than 40 professionals based across Asia, fluent in both English and their local dialects, and embedded in the markets they serve. Article content Since its founding in 2010, BGO's Asia series of strategies have invested approximately US$10 billion across 150 properties in 20 cities, consistently identifying and executing on high-conviction opportunities in Asia's most dynamic urban centers. Article content About BGO Article content BGO is a leading, global real estate investment management advisor and a globally-recognized provider of real estate services. BGO serves the interests of more than 750 institutional clients with approximately $86 billion USD of assets under management (as of March 31, 2025) and expertise in the asset management of office, industrial, multi-residential, retail and hospitality property across the globe. BGO has offices in 27 cities across thirteen countries with deep, local knowledge, experience, and extensive networks in the regions where we invest in and manage real estate assets on behalf of our clients in primary, secondary and co-investment markets. Article content BGO is a part of SLC Management, the institutional alternatives and traditional asset management business of Sun Life. Article content The assets under management shown above includes real estate equity and mortgage investments managed by the BGO group of companies and their affiliates, and as of 1Q21, includes certain uncalled capital commitments for discretionary capital until they are legally expired and excludes certain uncalled capital commitments where the investor has complete discretion over investment. Article content Article content Article content Contacts Article content